Arizona State Retirement System purchased a new stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Rating) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 10,152 shares of the company’s stock, valued at approximately $95,000.
Several other institutional investors and hedge funds have also recently modified their holdings of TSVT. Metropolitan Life Insurance Co NY bought a new stake in shares of 2seventy bio during the first quarter valued at approximately $25,000. Ameritas Investment Partners Inc. bought a new position in 2seventy bio in the first quarter worth approximately $30,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in 2seventy bio in the second quarter worth approximately $33,000. Point72 Hong Kong Ltd raised its stake in 2seventy bio by 371.0% in the third quarter. Point72 Hong Kong Ltd now owns 3,688 shares of the company’s stock worth $54,000 after buying an additional 2,905 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in 2seventy bio by 25.9% in the third quarter. Royal Bank of Canada now owns 4,430 shares of the company’s stock worth $66,000 after buying an additional 910 shares in the last quarter. Institutional investors own 89.47% of the company’s stock.
Analyst Ratings Changes
Separately, Wedbush reissued an “outperform” rating and issued a $26.00 price objective (up previously from $24.00) on shares of 2seventy bio in a research note on Thursday, May 4th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $29.00.
2seventy bio Trading Down 4.4 %
2seventy bio (NASDAQ:TSVT – Get Rating) last issued its quarterly earnings results on Thursday, March 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.53) by $0.93. The business had revenue of $56.18 million for the quarter, compared to the consensus estimate of $16.72 million. 2seventy bio had a negative return on equity of 60.95% and a negative net margin of 172.80%. On average, equities analysts forecast that 2seventy bio, Inc. will post -4.33 earnings per share for the current year.
About 2seventy bio
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma.
- Get a free copy of the StockNews.com research report on 2seventy bio (TSVT)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Want to see what other hedge funds are holding TSVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 2seventy bio, Inc. (NASDAQ:TSVT – Get Rating).
Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.